Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744223 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
A Phase 1 study of Lymphoma and Myelodysplastic Syndromes, sponsored by Bellicum Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 8
- Study locations
NCT01744223 is a Phase 1 study of Lymphoma and Myelodysplastic Syndromes that is active but no longer recruiting, run by Bellicum Pharmaceuticals. The registered enrollment target is 36 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT01744223, a Phase 1 study of Lymphoma and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Bellicum Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been "programmed" with a "self-destruct switch" so that if, after they have been given to the patient, the T cells start to react against the tissues (called "graft versus host" disease, GVHD), the T cells can be destroyed.
Conditions Studied
Interventions
- DRUG Rimiducid
- BIOLOGICAL BPX-501 dose 1
- BIOLOGICAL BPX-501 dose 2
- BIOLOGICAL BPX-501 dose 3
- BIOLOGICAL BPX-501 dose 4
Study Locations (8)
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Baylor Sammons Cancer Center - Dallas
- UT Southwestern Medical Center - Dallas
Georgia
- Emory University Winship Cancer Institute - Atlanta
Ohio
- University Hospitals of Cleveland - Cleveland
Oregon
- Oregon Health & Science University - Portland
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-03 |
| Est. Completion | 2032-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744223
The ClinicalTrials.gov registry entry for NCT01744223 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is Bellicum Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Rimiducid is the first listed.
NCT01744223 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT01744223 about?
NCT01744223 is a clinical study titled "Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant". This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the lab...
What is the current status of trial NCT01744223?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-03. Estimated completion is 2032-10.
What conditions does trial NCT01744223 study?
This clinical trial studies the following conditions: Lymphoma, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT01744223?
The interventions under investigation include: Rimiducid (DRUG), BPX-501 dose 1 (BIOLOGICAL), BPX-501 dose 2 (BIOLOGICAL), BPX-501 dose 3 (BIOLOGICAL), BPX-501 dose 4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01744223?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01744223 being conducted?
This trial has 8 study locations across Georgia, New York, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.